1. ¹Cancer Research UK Breast Cancer Biology Group, Division of Cancer Studies, Guy's King's and St Thomas's School of Medicine, Guy's Hospital, St Thomas Street, London SE1 9RT, UK
2. ²Department of Clinical Immunology, King's College Hospital, The Rayne Institute, 123 Coldharbour Lane, London SE5 9NU, UK

Correspondence: Dr J Maher, Cancer Research UK Breast Cancer Biology Group, Division of Cancer Studies, Guy's King's and St Thomas's School of Medicine, Guy's Hospital, St Thomas Street, London SE1 9RT, UK. E-mail: john.maher@cancer.org.uk

Received 12 February 2004; Revised 21 May 2004; Accepted 26 May 2004; Published online 13 July 2004.

Abstract

In light of their preeminent role in cellular immunity, there is considerable interest in targeting of cytotoxic T-lymphocytes to cancer. This review summarises the active and passive immunotherapeutic approaches under development to achieve this goal, emphasising how recent advances in tumour immunology and gene transfer have impacted upon this field.